使用芳香化酶抑制剂的乳腺癌患者维生素D水平变化的相关因素分析

Analysis the related factors of vitamin D level changes in breast cancer patients treated with AI

目的探讨影响使用芳香化酶抑制剂(aromataseinhibitor,AI)的乳腺癌患者维生素D水平的相关因素。方法通过收集乳腺癌患者的信息,对比使用AI和未使用AI组乳腺癌患者血清25(OH)D3的缺乏率。将使用AI患者的维生素D水平按照充足、不足、缺乏分类,采用单因素分析和Logistic回归模型探讨年龄、绝经时间、AI药物的使用时间、抗骨质疏松症药物的使用、抗骨质疏松症药物的种类和使用时间对25(OH)D3水平的影响。结果使用AI和未使用AI的乳腺癌患者25(OH)D3的缺乏率差异具有统计学意义(P<0.05),Logistic结果显示年龄、绝经时间、AI药物的使用时间是维生素D缺乏的危险因素,使用抗骨质疏松症药物是其保护因素(P<0.05)。结论使用AI的乳腺癌患者较易发生维生素D缺乏,诸多因素增加了使用AI的乳腺癌患者25(OH)D3水平降低的风险,需要临床关注。

Objective To explore the related factors influencing vitamin D levels in breast cancer patients treated with AI.Methods By collecting information about breast cancer patients,the deficiency rates of 25(OH)D3 was compared between using AI and not using AI breast cancer patients.Vitamin D levels in patients using AI was classified as sufficiency,insufficiency and deficiency,Univariate analysis and logistic regression model were used to explore the effects of age,menopause duration,AI duration,Use of anti-OP drugs and its type and duration on content of 25(OH)D3.Results The difference of vitamin D deficiency rate between using AI and not using AI breast cancer patients was statistically significant(P<0.05).Logistic result showed that age、menopause duration and AI duration were the risk factors for vitamin D deficiency,and the use of anti-OP drug was its protective factor(P<0.05).Conclusion Breast cancer patients using AI were more likely to suffer fromvitamin D deficiency,and many factors increase the risk of reduced 25(OH)D3 levels,which requires clinical attention.